The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...

In December, in the REDEFINE 1 Phase 3 trial, CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% ...

Novo Nordisk continues to build a case for its oral semaglutide GLP-1 class diabetes drug, with latest results from a phase 3a trial showing ... with a reduction of 3.7 kg compared to 1.1 kg ...

The subcutaneous therapy is CagriSema, a fixed dose combination of cagrilintide and semaglutide. In a phase 3 trial spanning 68 weeks, Novo Nordisk tested the drug’s efficacy compared to a placebo.

In December, in the REDEFINE 1 Phase 3 trial, CagriSema achieved a weight loss of 22.7% after 68 weeks compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and ...

Novo Nordisk is testing a Wegovy follow-up called CagriSema, based on semaglutide and amylin analogue cagrilintide, in phase 3, while Lilly has a triple agonist targeting GLP-1, GIP and glucagon ...

The subcutaneous therapy is CagriSema, a fixed dose combination of cagrilintide and semaglutide. In a phase 3 trial spanning 68 weeks, Novo Nordisk tested the drug’s efficacy compared to a placebo.

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

A phase 2 trial shows significant reduction in drinks per drinking day and weekly alcohol craving with low-dose semaglutide. HealthDay News — Low-dose semaglutide seems to reduce craving and certain ...

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

ASC47, an adipose-targeted muscle-preserving weight loss drug candidate for the treatment of obesity, demonstrated a half-life of up to 26 days and 40 days, respectively, in Phase Ib single ...

Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.